Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Parathyroid hormone-1 receptor down-regulation in kidneys from rats with chronic renal failure.

Edwards RM, Contino LC, Gellai M, Brooks DP.

Pharmacology. 2001 May;62(4):243-7.

PMID:
11360002
2.

Identification of a novel kidney-specific gene downregulated in acute ischemic renal failure.

Hu E, Chen Z, Fredrickson T, Gellai M, Jugus M, Contino L, Spurr N, Sims M, Halsey W, Van Horn S, Mao J, Sathe G, Brooks D.

Am J Physiol Renal Physiol. 2000 Sep;279(3):F426-39. Erratum in: Am J Physiol Renal Physiol 2001 Jun;280(6):section F following table of contents. Am J Physiol Renal Physiol 2001 Apr;280(4):section F following table of contents.

3.
4.

CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.

Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP.

J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6.

PMID:
9732378
5.

Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.

Ohlstein EH, Nambi P, Hay DW, Gellai M, Brooks DP, Luengo J, Xiang JN, Elliott JD.

J Pharmacol Exp Ther. 1998 Aug;286(2):650-6.

PMID:
9694916
6.

Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.

Douglas SA, Nambi P, Gellai M, Luengo JI, Xiang JN, Brooks DP, Ruffolo RR Jr, Elliott JD, Ohlstein EH.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S273-6.

PMID:
9595458
7.

Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1?

Nambi P, Gellai M, Wu HL, Prabhakar U.

Biochem Biophys Res Commun. 1997 Dec 8;241(1):212-4.

PMID:
9405259
8.

Contribution of endogenous endothelin-1 to the maintenance of vascular tone: role of nitric oxide.

Gellai M, De Wolf R, Fletcher T, Nambi P.

Pharmacology. 1997 Dec;55(6):299-308.

PMID:
9413859
9.

Identification and characterization of a novel endothelin receptor that binds both ETA- and ETB-selective ligands.

Nambi P, Pullen M, Kincaid J, Nuthulaganti P, Aiyar N, Brooks DP, Gellai M, Kumar C.

Mol Pharmacol. 1997 Oct;52(4):582-9.

PMID:
9380020
10.

Physiological role of endothelin in cardiovascular and renal hemodynamics: studies in animals.

Gellai M.

Curr Opin Nephrol Hypertens. 1997 Jan;6(1):64-8. Review.

PMID:
9051356
11.

Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat.

Gellai M, Fletcher T, Pullen M, Nambi P.

Am J Physiol. 1996 Jul;271(1 Pt 2):R254-61.

PMID:
8760228
12.

Identification of ETB receptor subtypes using linear and truncated analogs of ET.

Nambi P, Pullen M, Brooks DP, Gellai M.

Neuropeptides. 1995 Dec;29(6):331-6.

PMID:
8837960
13.

Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670.

Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP.

J Pharmacol Exp Ther. 1995 Oct;275(1):200-6.

PMID:
7562550
14.

Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist.

Aiyar N, Baker E, Vickery-Clark L, Ohlstein EH, Gellai M, Fredrickson TA, Brooks DP, Weinstock J, Weidley EF, Edwards RM.

Eur J Pharmacol. 1995 Sep 5;283(1-3):63-72.

PMID:
7498322
15.

Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670.

Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliott JD, Ohlstein EH.

Hypertension. 1995 Apr;25(4 Pt 2):818-22.

PMID:
7721437
16.

Identification and function of putative ETB receptor subtypes in the dog kidney.

Brooks DP, DePalma PD, Pullen M, Gellai M, Nambi P.

J Cardiovasc Pharmacol. 1995;26 Suppl 3:S322-5.

PMID:
8587403
17.

Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs.

Brooks DP, dePalma PD, Gellai M, Nambi P, Ohlstein EH, Elliott JD, Gleason JG, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1994 Nov;271(2):769-75.

PMID:
7965795
18.

Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats.

Gellai M, DeWolf R, Pullen M, Nambi P.

Kidney Int. 1994 Nov;46(5):1287-94.

19.

SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Frazee JS, et al.

Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052-6.

20.

BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.

Douglas SA, Gellai M, Ezekiel M, Ohlstein EH.

J Hypertens. 1994 May;12(5):561-7.

PMID:
7930556
21.

Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat.

Gellai M, Jugus M, Fletcher T, DeWolf R, Nambi P.

J Clin Invest. 1994 Feb;93(2):900-6.

22.
23.

Alpha 2-adrenoceptor antagonism attenuates the diuretic response to acute cold exposure.

Allen DE, Gellai M.

Am J Physiol. 1993 Sep;265(3 Pt 2):R689-96.

PMID:
8105704
24.

Influence of oxytocin on renal hemodynamics and sodium excretion.

Conrad KP, Gellai M, North WG, Valtin H.

Ann N Y Acad Sci. 1993 Jul 22;689:346-62. Review.

PMID:
8396871
25.

Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis.

Brooks DP, Giardina G, Gellai M, Dondio G, Edwards RM, Petrone G, DePalma PD, Sbacchi M, Jugus M, Misiano P, et al.

J Pharmacol Exp Ther. 1993 Jul;266(1):164-71.

PMID:
8392549
26.

Mechanisms for the diuresis of acute cold exposure: role for vasopressin?

Allen DE, Gellai M.

Am J Physiol. 1993 Mar;264(3 Pt 2):R524-32.

PMID:
8457004
27.

Rat kidney endothelin receptors in ischemia-induced acute renal failure.

Nambi P, Pullen M, Jugus M, Gellai M.

J Pharmacol Exp Ther. 1993 Jan;264(1):345-8.

PMID:
8423536
28.

Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats.

Ohlstein EH, Douglas SA, Ezekiel M, Gellai M.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S321-4.

PMID:
7509976
29.

The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.

Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, Ruffolo RR Jr, Weinstock J, Edwards RM.

J Pharmacol Exp Ther. 1992 Aug;262(2):595-601.

PMID:
1501114
30.

Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.

Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR Jr, Edwards RM, Gellai M.

Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):673-8.

PMID:
1635591
31.

Dopamine DA1 receptor agonist, fenoldopam, reverses glycine-induced hyperfiltration in rats.

Wang YX, Gellai M, Brooks DP.

Am J Physiol. 1992 Jun;262(6 Pt 2):F1055-60.

PMID:
1352429
32.
33.

The water diuretic effect of the alpha-2 adrenoceptor agonist, AGN 190851, is species-dependent.

Brooks DP, Edwards RM, Depalma PD, Fredrickson TA, Hieble JP, Gellai M.

J Pharmacol Exp Ther. 1991 Dec;259(3):1277-82.

PMID:
1684820
34.

Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific.

Brooks DP, Gellai M, DePalma PD, Edwards RM.

Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6.

PMID:
1659234
35.

Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.

Nichols AJ, Gellai M, Ruffolo RR Jr.

Fundam Clin Pharmacol. 1991;5(1):25-38.

PMID:
1712335
36.

Modulation of vasopressin antidiuretic action by renal alpha 2-adrenoceptors.

Gellai M.

Am J Physiol. 1990 Jul;259(1 Pt 2):F1-8. Review.

PMID:
2165355
37.

Hemodynamic responses to leukotriene receptor stimulation in conscious rats.

Allen DE, Gellai M.

Am J Physiol. 1990 Apr;258(4 Pt 2):R1034-41.

PMID:
2158749
38.

The pharmacology of carvedilol.

Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ.

Eur J Clin Pharmacol. 1990;38 Suppl 2:S82-8. Review.

PMID:
1974511
39.
40.
41.

Noncyclic vasopressin analogs are effective diuretics in conscious rats.

Uyehara CF, Caltabiano S, Kinter LB, Gellai M.

J Pharmacol Exp Ther. 1989 Dec;251(3):1128-33.

PMID:
2600807
42.

Mechanism of alpha 2-adrenoceptor agonist-induced diuresis.

Gellai M, Edwards RM.

Am J Physiol. 1988 Aug;255(2 Pt 2):F317-23.

PMID:
2900606
43.
44.

Oxytocin induces a transient increase in cytosolic free [Ca2+] in renal tubular epithelial cells: evidence for oxytocin receptors on LLC-PK1 cells.

Stassen FL, Heckman G, Schmidt D, Papadopoulos MT, Nambi P, Sarau H, Aiyar N, Gellai M, Kinter L.

Mol Pharmacol. 1988 Feb;33(2):218-24.

PMID:
2828915
45.

Localization of alpha 2-adrenoceptor-mediated increase in renal Na+, K+, and water excretion.

Stanton B, Puglisi E, Gellai M.

Am J Physiol. 1987 Jun;252(6 Pt 2):F1016-21.

PMID:
3035941
46.

Cardioinhibitory effect of atrial peptide in conscious rats.

Allen DE, Gellai M.

Am J Physiol. 1987 Mar;252(3 Pt 2):R610-6.

PMID:
2950778
47.

Renal effects of selective alpha-1 and alpha-2 adrenoceptor agonists in conscious, normotensive rats.

Gellai M, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1987 Mar;240(3):723-8.

PMID:
2882013
48.

Influence of oxytocin on renal hemodynamics and electrolyte and water excretion.

Conrad KP, Gellai M, North WG, Valtin H.

Am J Physiol. 1986 Aug;251(2 Pt 2):F290-6.

PMID:
3740276
49.

Contrasting views on the action of atrial peptides: lessons from studies of conscious animals.

Gellai M, Allen DE, Beeuwkes R 3rd.

Fed Proc. 1986 Aug;45(9):2387-91.

PMID:
2942424
50.

Supplemental Content

Loading ...
Support Center